

ACT Onco[®] + Report

PATIENT		
Identifier: 蔡富任		Patient ID: 43438182
Date of Birth: Jun 10, 1971		Gender: Male
Diagnosis: Spindle cell SCC		
ORDERING PHYSICIAN		
Name: 楊慕華醫師		Tel: 886-228712121
Facility: 臺北榮總		
Address: 臺北市北投區石牌路二段 201 號		
SPECIMEN		
Specimen ID: S11141854D	Collection site: Oropharynx	Type: FFPE tissue
Date received: Oct 25, 2022	Lab ID: AA-22-06404	D/ID: NA

ABOUT ACT Onco[®]+

The test is a next-generation sequencing (NGS)-based assay developed for efficient and comprehensive genomic profiling of cancers. This test interrogates coding regions of 440 genes associated with cancer treatment, prognosis and diagnosis. Genetic mutations detected by this test include small-scale mutations like single nucleotide variants (SNVs), small insertions and deletions (InDels) (≤ 15 nucleotides) and large-scale genomic alterations like copy number alterations (CNAs). The test also includes an RNA test, detecting fusion transcripts of 13 genes.

SUMMARY FOR ACTIONABLE VARIANTS

VARIANTS/Biomarkers WITH EVIDENCE OF CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Probable Effects in Patient's Cancer Type		Probable Sensitive in Other Cancer Types
	Sensitive	Resistant	
Not detected			

VARIANTS/Biomarkers WITH POTENTIAL CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Possibly Sensitive	Possibly Resistant
POLB S104fs	Olaparib	-

Note:

- The above summary tables present genomic variants and biomarkers based on the three-tiered approach proposed by US FDA for reporting tumor profiling NGS testing. "Variants/biomarkers with evidence of clinical significance" refers to mutations that are widely recognized as standard-of-care biomarkers (FDA level 2/AMP tier 1). "Variants/biomarkers with potential clinical significance" refers to mutations that are not included in the standard of care but are informational for clinicians, which are commonly biomarkers used as inclusion criteria for clinical trials (FDA level 3/AMP tier 2).
- The therapeutic agents and possible effects to a given drug are based on mapping the variants/biomarkers with ACT Genomics clinical knowledge database. The mapping results only provide information for reference, but not medical recommendation.
- Please refer to corresponding sections for more detailed information about genomic alteration and clinical relevance listed above.

ACTOnco® + Report

TESTING RESULTS

VARIANT(S) WITH CLINICAL RELEVANCE

- Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Allele Frequency
CASP8	R413*	14.6%
POLB	S104fs	7.3%
TP53	R306*	10.6%
TP53	R273H	10.3%

- Copy Number Alterations

Chromosome	Gene	Variation	Copy Number
Not detected			

- Fusions

Fusion Gene & Exon	Transcript ID
No fusion gene detected in this sample	

- Immune Checkpoint Inhibitor (ICI) Related Biomarkers

Biomarker	Results
Tumor Mutational Burden (TMB)	3.8 muts/Mb
Microsatellite Instability (MSI)	Microsatellite stable (MSS)

Note:

- Variant(s) enlisted in the SNV table may currently exhibit no relevance to treatment response prediction. Please refer to INTERPRETATION for more biological information and/or potential clinical impacts of the variants.
- Loss of heterozygosity (LOH) information was used to infer tumor cellularity. Copy number alteration in the tumor was determined based on 30% tumor purity.
- TMB was calculated by using the sequenced regions of ACTOnco® to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The threshold for high mutation load is set at ≥ 7.5 mutations per megabase. TMB, microsatellite status and gene copy number deletion cannot be determined if calculated tumor purity is $< 30\%$.

ACT Onco[®] + Report

THERAPEUTIC IMPLICATIONS TARGETED THERAPIES

Genomic Alterations	Therapies	Effect
Level 4		
POLB S104fs	Olaparib	sensitive

Therapies associated with benefit or lack of benefit are based on biomarkers detected in this tumor and published evidence in professional guidelines or peer-reviewed journals.

Level	Description
1	FDA-recognized biomarkers predictive of response or resistance to FDA approved drugs in this indication
2	Standard care biomarkers (recommended by the NCCN guideline) predictive of response or resistance to FDA approved drugs in this indication
3A	Biomarkers predictive of response or resistance to therapies approved by the FDA or NCCN guideline in a different cancer type
3B	Biomarkers that serve as inclusion criteria for clinical trials (minimal supportive data required)
4	Biomarkers that show plausible therapeutic significance based on small studies, few case reports, or preclinical studies

ACT Onco[®] + Report

IMMUNE CHECKPOINT INHIBITORS (ICIs)

No genomic alterations detected to confer sensitivity or lack of benefit to immune checkpoint therapies.

- Other Biomarkers with Potential Clinical Effects for ICIs

Genomic Alterations	Potential Clinical Effects
Not detected	

Note: Tumor non-genomic factors, such as patient germline genetics, PDL1 expression, tumor microenvironment, epigenetic alterations or other factors not provided by this test may affect ICI response.

CHEMOTHERAPIES

Genomic Alterations	Therapies	Effect	Level of Evidence	Cancer Type
TP53 R273H	Platinum- and taxane-based regimens	Less sensitive	Clinical	Ovarian cancer

HORMONAL THERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to hormonal therapies.

OTHERS

Pharmacogenomic implication

Gene	Detection Site	Genotype	Drug Impact	Level of Evidence*
UGT1A1	rs4148323	AG	Irinotecan-based regimens	Level 1B

Clinical Interpretation:

Patients with the AG genotype and cancer who are treated with irinotecan-based regimens may have an increased risk of diarrhea and neutropenia as compared to patients with the GG genotype, or a decreased risk of diarrhea and neutropenia compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of diarrhea and neutropenia.

* Level of evidence was defined by PharmGKB (<https://www.pharmgkb.org/page/clinAnnLevels>)

Level 1A: Clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or an FDA-approved drug label annotation.

Level 1B: Clinical annotations describe variant-drug combinations with a high level of evidence supporting the association but no variant-specific prescribing guidance in an annotated clinical guideline or FDA drug label.

Level 2A: Variants in Level 2A clinical annotations are found in PharmGKB's Tier 1 Very Important Pharmacogenes (VIPs). These variants are in known pharmacogenes, implying causation of drug phenotype is more likely.

Note:

Therapeutic implications provided in the test are based solely on the panel of 440 genes sequenced. Therefore, alterations in genes not covered in this panel, epigenetic and post-transcriptional and post-translational factors may also determine a patient's response to therapies. In addition, several other patient-associated clinical factors, including but not limited to, prior lines of therapies received, dosage and combinations with other therapeutic agents, patient's cancer types, sub-types, and/or stages, may also determine the patient's clinical response to therapies.

ACT Onco[®] + Report

VARIANT INTERPRETATION

CASP8 R413*

Biological Impact

CASP8 (cysteine-aspartic acid protease 8) gene encodes a member of the caspase family which plays essential roles in the of death receptor-induced apoptosis^{[1][2]}, antigen receptor-mediated NF-κB activation in T cell and B cells^{[3][4][5]}, suppressing cellular necrosis, and regulating autophagy^{[6][7]}. Moreover, CASP8 has been reported to modulate cell adhesion and motility^{[8][9][10][11]}. Inactivating somatic mutations of CASP8 have been reported in hepatocellular carcinoma^[12], colorectal cancer^[13], oral squamous cell carcinomas^[14], head and neck squamous cell carcinoma^[15], and gastric cancer^[16]. Furthermore, loss of CASP8 expression via the promoter hypermethylation has been observed in neuroblastoma^{[17][18]}.

R413* mutation results in a premature truncation of the CASP8 protein at amino acid 413 (UniProtKB). This mutation is predicted to lead to a loss of CASP8 function, despite not having characterized in the literature.

Therapeutic and prognostic relevance

Weak expression of CASP8 was reported as an independent prognostic factor for unfavorable progression-free survival in a study of childhood medulloblastoma patients (n=77)^[19]. However, higher expression of CASP8 was correlated with shorter disease-free survival in stage III colon carcinoma and shorter overall survival in colorectal cancer^{[20][21]}. Of note, though the expression of CASP8 has been intensively investigated in neuroblastoma, a previous study showed that CASP8 expression levels were not correlated with event-free survival or overall survival in neuroblastoma^[22]. In head and neck squamous cell carcinoma (HNSCC), CASP8 loss-of-function mutations has been associated with radioresistance and poor outcomes. However, knockdown of CASP8 could sensitize HNSCC to birinapant (a SMAC mimetic) and Z-VAD-FMK combination treatment in vitro^[23].

POLB S104fs

Biological Impact

DNA polymerase beta (POLB) maintains genome integrity by participating in base excision repair. POLB gene is upregulated by CREB1 transcription factor's binding to the cAMP response element (CRE) present in the promoter of the POLB gene in response to exposure to alkylating agents^{[24][25]}. Overexpression of POLB mRNA has been correlated with a number of cancer types, whereas deficiencies in POLB results in hypersensitivity to alkylating agents, induced apoptosis, and chromosomal breaking^[26]. Of note, destabilizing mutations of POLB have been reported to associate with higher tumor mutational burden and lower somatic copy number alterations^[27].

S104fs mutation results in a change in the amino acid sequence beginning at 104, likely to cause premature truncation of the functional POLB protein (UniProtKB). This mutation is predicted to lead to a loss of POLB protein function, despite not being characterized in the literature.

Therapeutic and prognostic relevance

In a preclinical study, POLB-deficient cells were sensitive to olaparib treatment in vitro^[28]. Low expression of POLB was associated with high grade, lymph node positivity and poor survival in breast cancer. Of note, in estrogen receptor (ER)-positive or luminal A subgroup of breast cancer patients, low expression of POLB was correlated with poor survival when treated with tamoxifen^[29]. Decreased expression of POLB was correlated with increased sensitivity to cisplatin but not oxaliplatin in vitro^[30].

ACT Onco[®] + Report

TP53 R273H, R306*

Biological Impact

TP53 encodes the p53 protein, a crucial tumor suppressor that orchestrates essential cellular processes including cell cycle arrest, senescence and apoptosis^[31]. TP53 is a proto-typical haploinsufficient gene, such that loss of a single copy of TP53 can result in tumor formation^[32].

TP53 R273H is a hotspot mutation located in the DNA binding domain (DBD) of the p53 protein^[33]. This mutation gains oncogenic functions to promote cell migration and cell growth in vitro^{[34][35][36]}.

R306* mutation results in a premature truncation of the p53 protein at amino acid 306 (UniProtKB). This mutation is predicted to lead to a loss of p53 function, despite not having characterized in the literature.

Therapeutic and prognostic relevance

Despite having a high mutation rate in cancers, there are currently no approved targeted therapies for TP53 mutations. A phase II trial demonstrated that Wee1 inhibitor (AZD1775) in combination with carboplatin was well tolerated and showed promising anti-tumor activity in TP53-mutated ovarian cancer refractory or resistant (< 3 months) to standard first-line therapy (NCT01164995)^[37].

In a retrospective study (n=19), advanced sarcoma patients with TP53 loss-of-function mutations displayed improved progression-free survival (208 days versus 136 days) relative to patients with wild-type TP53 when treated with pazopanib^[38]. Results from another Phase I trial of advanced solid tumors (n=78) demonstrated that TP53 hotspot mutations are associated with better clinical response to the combination of pazopanib and vorinostat^[39].

Advanced solid tumor and colorectal cancer patients harboring a TP53 mutation have been shown to be more sensitive to bevacizumab when compared with patients harboring wild-type TP53^{[40][41][42]}. In a pilot trial (n=21), TP53-negative breast cancer patients demonstrated increased survival following treatment with bevacizumab in combination with chemotherapy agents, Adriamycin (doxorubicin) and Taxotere (docetaxel)^[43]. TP53 mutations were correlated with poor survival of advanced breast cancer patients receiving tamoxifen or primary chemotherapy^{[44][45]}. In a retrospective study of non-small cell lung cancer (NSCLC), TP53 mutations were associated with high expression of VEGF-A, the primary target of bevacizumab, offering a mechanistic explanation for why patients exhibit improved outcomes after bevacizumab treatment when their tumors harbor mutant TP53 versus wild-type TP53^[46].

TP53 oncomorphic mutations, including P151S, Y163C, R175H, L194R, Y220C, R248Q, R248W, R273C, R273H, R273L and R282W have been shown to predict resistance to platinum- and taxane-based chemotherapy in advanced serous ovarian carcinoma patients^[47]. A preclinical study demonstrated that cells expressing TP53 R273H showed increased synergistic sensitivity to the talazoparib in combination with temozolomide in vitro^{[48][49]}.

ACT Onco® + Report

US FDA-APPROVED DRUG(S)

Olaparib (LYNPARZA)

Olaparib is an oral, small molecule inhibitor of poly (ADP-ribose) polymerase-1, -2, and -3 (PARP-1, -2, -3). Olaparib is developed by KuDOS Pharmaceuticals and marketed by AstraZeneca under the trade name LYNPARZA.

- FDA Approval Summary of Olaparib (LYNPARZA)

OlympiA NCT02032823	Her2-negative high-risk early breast cancer (Approved on 2022/03/11)
	HER2-/gBRCA mutation Olaparib vs. Placebo [invasive disease-free survival (IDFS)(M):]
PROfound ^[50] NCT02987543	Prostate cancer (Approved on 2020/05/19)
	HRR genes mutation Olaparib vs. Enzalutamide or abiraterone acetate [PFS(M): 5.8 vs. 3.5]
PAOLA-1 ^[51] NCT02477644	Ovarian cancer (Approved on 2020/05/08)
	HRD+ Olaparib + bevacizumab vs. Placebo + bevacizumab [PFS(M): 37.2 vs. 17.7]
POLO ^[52] NCT02184195	Pancreatic adenocarcinoma (Approved on 2019/12/27)
	gBRCA mutation Olaparib vs. Placebo [ORR(%): 23.0 vs. 12.0, PFS(M): 7.4 vs. 3.8]
SOLO-1 ^[53] NCT01844986	Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma (Approved on 2018/12/19)
	gBRCA mutation or sBRCA mutation Olaparib vs. Placebo [PFS(M): NR vs. 13.8]
OlympiAD ^[54] NCT02000622	Breast cancer (Approved on 2018/02/06)
	HER2-/gBRCA mutation Olaparib vs. Chemotherapy [PFS(M): 7 vs. 4.2]
SOLO-2/ENGOT-Ov21 ^[55] NCT01874353	Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma (Approved on 2017/08/17)
	gBRCA mutation Olaparib vs. Placebo [PFS(M): 19.1 vs. 5.5]
Study19 ^[56] NCT00753545	Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma (Approved on 2017/08/17)
	- Olaparib vs. Placebo [PFS(M): 8.4 vs. 4.8]

D=day; W=week; M=month

ACT Onco[®] + Report

ONGOING CLINICAL TRIALS

Trials were searched by applying filters: study status, patient's diagnosis, intervention, location and/or biomarker(s). Please visit <https://clinicaltrials.gov> to search and view for a complete list of open available and updated matched trials.

No trial has been found.

ACT Onco[®] + Report


SUPPLEMENTARY INFORMATION OF TESTING RESULTS DETAILED INFORMATION OF VARIANTS WITH CLINICAL RELEVANCE

- Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
CASP8	R413*	9	c.1237C>T	NM_033355	COSM2907151	14.6%	858
POLB	S104fs	5	c.309_318del	NM_002690	-	7.3%	342
TP53	R273H	8	c.818G>A	NM_000546	COSM10660	10.3%	677
TP53	R306*	8	c.916C>T	NM_000546	COSM10663	10.6%	954

- Copy Number Alterations

Observed copy number (CN) for each evaluated position is shown on the y-axis. Regions referred to as amplification or deletion are shown in color. Regions without significant changes are represented in gray.



ACT Onco[®] + Report

OTHER DETECTED VARIANTS

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
ABL1	L603F	11	c.1809G>C	NM_005157	-	10.7%	779
ADGRA2	Splice region	-	c.1833+7G>A	NM_032777	-	59.4%	180
ADGRA2	L474W	10	c.1421T>G	NM_032777	-	49.5%	455
AKT2	Splice region	-	c.573+8C>T	NM_001626	-	49.9%	515
ARID1B	E1985Q	19	c.5953G>C	NM_017519	COSM5781482	10.7%	1949
BMPR1A	R238Q	9	c.713G>A	NM_004329	COSM4573867	51.1%	985
CSF1R	T621M	14	c.1862C>T	NM_005211	COSM4970976	51.4%	551
ERCC2	M677I	21	c.2031G>A	NM_000400	-	53.6%	153
FLT1	Y109*	3	c.327T>G	NM_002019	-	9.3%	1322
KDM5A	E436G	10	c.1307A>G	NM_001042603	-	9.8%	264
MRE11	P230L	8	c.689C>T	NM_005591	-	54.2%	642
NEFH	E960D	4	c.2880G>T	NM_021076	-	54.8%	549
PIK3C2B	C691W	14	c.2073C>G	NM_002646	COSM5749128	49.5%	671
PTCH1	Splice region	-	c.2560+7C>T	NM_000264	-	48.4%	1396
PTPR	A1326G	28	c.3977C>G	NM_007050	-	10.0%	740
RAD54L	L621P	16	c.1862T>C	NM_003579	-	45.0%	451
SDHA	R554Q	12	c.1661G>A	NM_004168	-	50.6%	462
TSC2	A1141T	30	c.3421G>A	NM_000548	-	47.2%	106
USH2A	Splice region	-	c.6958-5C>T	NM_206933	-	51.1%	272
USH2A	V2228E	35	c.6683T>A	NM_206933	-	49.6%	728


Note:

- This table enlists variants detected by the panel other than those with clinical relevance (reported in Testing Result section). The clinical impact of a genetic variant is determined according to ACT Genomics in-house clinical knowledge database. A negative result does not necessarily indicate absence of biological effect on the tumor. Some variants listed here may possibly have preclinical data or may show potential clinical relevance in the future.

ACT Onco[®] + Report

TEST DETAILS

SPECIMEN RECEIVED AND PATHOLOGY REVIEW



- Collection date: Oct 17, 2022
- Facility retrieved: 臺北榮總
- H&E-stained section No.: S11141854D
- Collection site: Oropharynx
- Examined by: Dr. Chien-Ta Chiang
 1. The percentage of viable tumor cells in total cells in the whole slide (%): 10%
 2. The percentage of viable tumor cells in total cells in the encircled areas in the whole slide (%): 30%
 3. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the whole slide (%): 5%
 4. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the encircled areas in the whole slide (%): 5%
 5. Additional comment: NA
- Manual macrodissection: Performed on the highlighted region
- The outline highlights the area of malignant neoplasm annotated by a pathologist.

RUN QC

- Panel: ACTOnco[®]+

DNA test

- Mean Depth: 769x
- Target Base Coverage at 100x: 96%

RNA test

- Average unique RNA Start Sites per control GSP2: 163

ACT Onco[®] + Report

LIMITATIONS

1. This test does not provide information of variant causality and does not detect variants in non-coding regions that could affect gene expression. This report does not report polymorphisms and we do not classify whether a mutation is germline or somatic. Variants identified by this assay were not subject to validation by Sanger or other technologies.
2. The possibility cannot be excluded that certain pathogenic variants detected by other sequencing tools may not be reported in the test because of technical limitation of bioinformatics algorithm or the NGS sequencing platform, e.g. low coverage.
3. This test has been designed to detect fusions in 13 genes sequenced. Therefore, fusion in genes not covered by this test would not be reported. For novel fusions detected in this test, Sanger sequencing confirmation is recommended if residue specimen is available.

NEXT-GENERATION SEQUENCING (NGS) METHODS

DNA test

Extracted genomic DNA was amplified using primers targeting coding exons of analyzed genes and subjected to library construction. Barcoded libraries were subsequently conjugated with sequencing beads by emulsion PCR and enriched using Ion Chef system. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific).

Raw reads generated by the sequencer were mapped to the hg19 reference genome using the Ion Torrent Suite. Coverage depth was calculated using Torrent Coverage Analysis plug-in. Single nucleotide variants (SNVs) and short insertions/deletions (InDels) were identified using the Torrent Variant Caller plug-in. VEP (Variant Effect Predictor) was used to annotate every variant using databases from Clinvar, COSMIC and Genome Aggregation database. Variants with coverage ≥ 20 , allele frequency $\geq 5\%$ and actionable variants with allele frequency $\geq 2\%$ were retained. This test provides uniform coverage of the targeted regions, enabling target base coverage at $100\times \geq 85\%$ with a mean coverage $\geq 500\times$.

Variants reported in Genome Aggregation database with $> 1\%$ minor allele frequency (MAF) were considered as polymorphisms. ACT Genomics in-house database was used to determine technical errors. Clinically actionable and biologically significant variants were determined based on the published medical literature.

The copy number alterations (CNAs) were predicted as described below:

Amplicons with read counts in the lowest 5th percentile of all detectable amplicons and amplicons with a coefficient of variation ≥ 0.3 were removed. The remaining amplicons were normalized to correct the pool design bias. ONCOCNV (an established method for calculating copy number aberrations in amplicon sequencing data by Boeva et al., 2014) was applied for the normalization of total amplicon number, amplicon GC content, amplicon length, and technology-related biases, followed by segmenting the sample with a gene-aware model. The method was used as well for establishing the baseline of copy number variations.

Tumor mutational burden (TMB) was calculated by using the sequenced regions of ACTOnco[®] to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The TMB calculation predicted somatic variants and applied a machine learning model with a cancer hotspot correction. TMB may be reported as "TMB-High", "TMB-Low" or "Cannot Be Determined". TMB-High corresponds to ≥ 7.5 mutations per megabase (Muts/Mb); TMB-Low corresponds to < 7.5 Muts/Mb. TMB is reported as "Cannot Be Determined" if the tumor purity of the sample is $< 30\%$.

Classification of microsatellite instability (MSI) status is determined by a machine learning prediction algorithm. The change of a number of repeats of different lengths from a pooled microsatellite stable (MSS) baseline in > 400 genomic loci are used as the features for the algorithm. The final output of the results is either microsatellite Stable (MSS) or microsatellite instability high (MSI-H).

ACT Onco[®] + Report

RNA test

Extracted RNA was reverse-transcribed and subjected to library construction. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific). To ensure sequencing quality for fusion variant analysis, the average unique RNA Start Sites (SS) per control Gene Specific Primer 2 (GSP 2) should be ≥ 10 .

The fusion analysis pipeline aligned sequenced reads to the human reference genome, identified regions that map to noncontiguous regions of the genome, applied filters to exclude probable false-positive events and, annotated previously characterized fusion events according to Quiver Gene Fusion Database, a curated database owned and maintained by ArcherDX. In general, samples with detectable fusions need to meet the following criteria: (1) Number of unique start sites (SS) for the GSP2 ≥ 3 ; (2) Number of supporting reads spanning the fusion junction ≥ 5 ; (3) Percentage of supporting reads spanning the fusion junction $\geq 10\%$; (4) Fusions annotated in Quiver Gene Fusion Database.

DATABASE USED

- Reference genome: Human genome sequence hg19
- COSMIC v.92
- Genome Aggregation database r2.1.1
- ClinVar (version 20210404)
- ACT Genomics in-house database
- Quiver Gene Fusion Database version 5.1.18

Variant Analysis:

醫檢師張筑芃 博士
Chu-Yuan Chang Ph.D.
檢字第 020115 號



Sign Off

解剖病理專科醫師王業翰
Yeh-Han Wang M.D.
病解字第 000545 號



ACT Onco[®] + Report

GENE LIST SNV & CNV

ABCB1*	ABCC2*	ABCG2*	ABL1	ABL2	ADAMTS1	ADAMTS13	ADAMTS15	ADAMTS16	ADAMTS18	ADAMTS6	ADAMTS9
ADAMTSL1	ADGRA2	ADH1C*	AKT1	AKT2	AKT3	ALDH1A1*	ALK	AMER1	APC	AR	ARAF
ARID1A	ARID1B	ARID2	ASXL1	ATM	ATR	ATRX	AURKA	AURKB	AXIN1	AXIN2	AXL
B2M	BAP1	BARD1	BCL10	BCL2*	BCL2L1	BCL2L2*	BCL6	BCL9	BCOR	BIRC2	BIRC3
BLM	BMP1R1A	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1	BTG2*	BTB	BUB1B	CALR
CANX	CARD11	CASP8	CBFB	CBL	CCNA1	CCNA	CCNB1	CCNB2	CCNB3	CCND1	CCND2
CCND3	CCNE1	CCNE2	CCNH	CD19	CD274	CD58	CD70*	CD79A	CD79B	CDC73	CDH1
CDK1	CDK12	CDK2	CDK4	CDK5	CDK6	CDK7	CDK8	CDK9	CDKN1A	CDKN1B	CDKN2A
CDKN2B	CDKN2C	CEBPA*	CHEK1	CHEK2	CIC	CREBBP	CRKL	CRLF2	CSF1R	CTCF	CTLA4
CTNNA1	CTNNB1	CUL3	CYLD	CYP1A1*	CYP2B6*	CYP2C19*	CYP2C8*	CYP2D6	CYP2E1*	CYP3A4*	CYP3A5*
DAXX	DCUN1D1	DDR2	DICER1	DNMT3A	DOT1L	DPYD	DTX1	E2F3	EGFR	EP300	EPCAM
EPHA2	EPHA3	EPHA5	EPHA7	EPHB1	ERBB2	ERBB3	ERBB4	ERCC1	ERCC2	ERCC3	ERCC4
ERCC5	ERG	ESR1	ESR2	ETV1	ETV4	EZH2	FAM46C	FANCA	FANCC	FANCD2	FANCE
FANCF	FANCG	FANCL	FAS	FAT1	FBXW7	FCGR2B	FGF1*	FGF10	FGF14	FGF19*	FGF23
FGF3	FGF4*	FGF6	FGFR1	FGFR2	FGFR3	FGFR4	FH	FLCN	FLT1	FLT3	FLT4
FOXL2*	FOXP1	FRG1	FUBP1	GATA1	GATA2	GATA3	GNA11	GNA13	GNAQ	GNAS	GREM1
GRIN2A	GSK3B	GSTP1*	GSTT1*	HGF	HIF1A	HIST1H1C*	HIST1H1E*	HNF1A	HR	HRAS*	HSP90AA1
HSP90AB1	HSPA4	HSPA5	IDH1	IDH2	IFNL3*	IGF1	IGF1R	IGF2	IKBKB	IKBKE	IKZF1
IL6	IL7R	INPP4B	INSR	IRF4	IRS1	IRS2*	JAK1	JAK2	JAK3	JUN*	KAT6A
KDM5A	KDM5C	KDM6A	KDR	KEAP1	KIT	KMT2A	KMT2C	KMT2D	KRAS	LCK	LIG1
LIG3	LMO1	LRP1B	LYN	MALT1	MAP2K1	MAP2K2	MAP2K4	MAP3K1	MAP3K7	MAPK1	MAPK3
MAX	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1	MET	MITF	MLH1	MPL	MRE11
MSH2	MSH6	MTHFR*	MTOR	MUC16	MUC4	MUC6	MUTYH	MYC	MYCL	MYCN	MYD88
NAT2*	NBN	NEFH	NF1	NF2	NFE2L2	NFKB1	NFKBIA	NKX2-1*	NOTCH1	NOTCH2	NOTCH3
NOTCH4	NPM1	NQO1*	NRAS	NSD1	NTRK1	NTRK2	NTRK3	PAK3	PALB2	PARP1	PAX5
PAX8	PBRM1	PDCD1	PDCD1LG2	PDGFRA	PDGFRB	PDIA3	PGF	PHOX2B*	PIK3C2B	PIK3C2G	PIK3C3
PIK3CA	PIK3CB	PIK3CD	PIK3CG	PIK3R1	PIK3R2	PIK3R3	PIM1	PMS1	PMS2	POLB	POLD1
POLE	PPARG	PPP2R1A	PRDM1	PRKAR1A	PRKCA	PRKCB	PRKCG	PRKCI	PRKCQ	PRKDC	PRKN
PSMB8	PSMB9	PSME1	PSME2	PSME3	PTCH1	PTEN	PTGS2	PTPN11	PTPRD	PTPRT	RAC1
RAD50	RAD51	RAD51B	RAD51C	RAD51D	RAD52	RAD54L	RAF1	RARA	RB1	RBM10	RECQL4
REL	RET	RHOA	RICTOR	RNF43	ROS1	RPPH1	RPTOR	RUNX1	RUNX1T1	RXRA	SDHA
SDHB	SDHC	SDHD	SERPINB3	SERPINB4	SETD2	SF3B1	SGK1	SH2D1A*	SLC19A1*	SLC22A2*	SLC1B1*
SLC1B3*	SMAD2	SMAD3	SMAD4	SMARCA4	SMARCB1	SMO	SOC1*	SOX2*	SOX9	SPEN	SPOP
SRC	STAG2	STAT3	STK11	SUFU	SYK	SYNE1	TAF1	TAP1	TAP2	TAPBP	TBX3
TEK	TERT	TET1	TET2	TGFBR2	TMSB4X*	TNF	TNFAIP3	TNFRSF14	TNFSF11	TOP1	TP53
TPMT*	TSC1	TSC2	TSHR	TYMS	U2AF1	UBE2A*	UBE2K	UBR5	UGT1A1*	USH2A	VDR*
VEGFA	VEGFB	VHL	WT1	XIAP	XPO1	XRCC2	ZNF217				

*Analysis of copy number alterations NOT available.

FUSION

ALK	BRAF	EGFR	FGFR1	FGFR2	FGFR3	MET	NRG1	NTRK1	NTRK2	NTRK3	RET	ROS1
-----	------	------	-------	-------	-------	-----	------	-------	-------	-------	-----	------

ACT Onco[®] + Report

APPENDIX

POSSIBLE THERAPEUTIC IMPLICATIONS FOR HETEROZYGOUS DELETION

Not Applicable.

SIGNALING PATHWAYS AND MOLECULAR-TARGETED AGENTS

Not Applicable.

ACT Onco[®] + Report

DISCLAIMER

法律聲明

本檢驗報告僅提供專業醫療參考，結果需經專業醫師解釋及判讀。基因突變資訊非必具備藥物或治療有效性指標，反之亦然。本檢驗報告提供之用藥指引不聲明或保證其臨床有效性，反之亦然。本基因檢測方法係由本公司研究開發，已經過有效性測試。

本檢驗報告非經本公司許可，不得私自變造、塗改，或以任何方式作為廣告及其他宣傳之用途。

本公司於提供檢驗報告後，即已完成本次契約義務，後續之報告解釋、判讀及用藥、治療，應自行尋求相關專業醫師協助，若需將報告移件其他醫師，本人應取得該醫師同意並填寫移件申請書，主動告知行動基因，行動基因僅能配合該醫師意願與時間提供醫師解說。

醫療決策需由醫師決定

任何治療與用藥需經由醫師在考慮病患所有健康狀況相關資訊包含健檢、其他檢測報告和病患意願後，依照該地區醫療照護標準由醫師獨立判斷。醫師不應僅依據單一報告結果(例如本檢測或本報告書內容)做決策。

基因突變與用藥資訊並非依照有效性排序

本報告中列出之生物標記變異與藥物資訊並非依照潛在治療有效性排序。

證據等級

藥物潛在臨床效益(或缺乏潛在臨床效益)的實證證據是依據至少一篇臨床療效個案報告或臨床前試驗做為評估。本公司盡力提供適時及準確之資料，但由於醫學科技之發展日新月異，本公司不就本報告提供的資料是否為準確、適宜或最新作保證。

責任

本檢驗報告僅提供專業醫療參考，本公司及其員工不對任何由使用本報告之內容引起的直接、間接、特殊、連帶或衍生的損失或損害承擔責任。

ACT Onco[®] + Report

REFERENCE

1. PMID: 25617598; 2015, Semin Cell Dev Biol;39():20-5
Targeting extrinsic apoptosis in cancer: Challenges and opportunities.
2. PMID: 18073771; 2008, Nat Rev Mol Cell Biol;9(3):231-41
Apoptosis: controlled demolition at the cellular level.
3. PMID: 11002417; 2000, Oncogene;19(39):4451-60
Activation of the NF-kappaB pathway by caspase 8 and its homologs.
4. PMID: 10753878; 2000, J Biol Chem;275(15):10838-44
Activation of NF-kappaB by FADD, Casper, and caspase-8.
5. PMID: 15746428; 2005, Science;307(5714):1465-8
Requirement for caspase-8 in NF-kappaB activation by antigen receptor.
6. PMID: 24467204; 2014, Curr Mol Med;14(2):246-54
Caspase-8 as a regulator of tumor cell motility.
7. PMID: 24856110; 2014, Semin Immunol;26(3):246-52
Functions of caspase 8: the identified and the mysterious.
8. PMID: 18089800; 2007, Cancer Res;67(24):11704-11
Novel noncatalytic role for caspase-8 in promoting SRC-mediated adhesion and Erk signaling in neuroblastoma cells.
9. PMID: 18089778; 2007, Cancer Res;67(24):11505-9
Caspase-8 interacts with the p85 subunit of phosphatidylinositol 3-kinase to regulate cell adhesion and motility.
10. PMID: 18216014; 2008, J Biol Chem;283(19):13031-4
Identification of a critical tyrosine residue in caspase 8 that promotes cell migration.
11. PMID: 16618751; 2006, Cancer Res;66(8):4273-8
Caspase-8 promotes cell motility and calpain activity under nonapoptotic conditions.
12. PMID: 15531912; 2005, Oncogene;24(1):141-7
Caspase-8 gene is frequently inactivated by the frameshift somatic mutation 1225_1226delTG in hepatocellular carcinomas.
13. PMID: 12949717; 2003, Gastroenterology;125(3):708-15
Inactivating mutations of caspase-8 gene in colorectal carcinomas.
14. PMID: 24292195; 2013, Nat Commun;4():2873
Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups.
15. PMID: 21798893; 2011, Science;333(6046):1157-60
The mutational landscape of head and neck squamous cell carcinoma.
16. PMID: 15705878; 2005, Cancer Res;65(3):815-21
CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas.
17. PMID: 14499695; 2003, Cancer Genet Cytogenet;146(1):41-7
Caspase 3 and 8 deficiency in human neuroblastoma.
18. PMID: 17064406; 2006, BMC Cancer;6():254
Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma.
19. PMID: 14695141; 2003, Clin Cancer Res;9(17):6401-9
Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma.

ACT Onco[®] + Report

20. PMID: 20013803; 2010, Int J Cancer;127(4):873-80
Expression and prognostic significance of APAF-1, caspase-8 and caspase-9 in stage II/III colon carcinoma: caspase-8 and caspase-9 is associated with poor prognosis.
21. PMID: 29355114; 2018, Cancer Biomark;21(4):899-908
Synergistic role of Caspase-8 and Caspase-3 expressions: Prognostic and predictive biomarkers in colorectal cancer.
22. PMID: 17047064; 2006, Cancer Res;66(20):10016-23
Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastoma.
23. PMID: 33108350; 2020, JCI Insight;5(23):
Caspase-8 loss radiosensitizes head and neck squamous cell carcinoma to SMAC mimetic-induced necroptosis.
24. PMID: 12674496; 2003, Biol Chem;384(1):19-23
DNA polymerase beta gene expression: the promoter activator CREB-1 is upregulated in Chinese hamster ovary cells by DNA alkylating agent-induced stress.
25. PMID: 8702497; 1996, J Biol Chem;271(31):18508-13
Activation of the human DNA polymerase beta promoter by a DNA-alkylating agent through induced phosphorylation of cAMP response element-binding protein-1.
26. PMID: 12067997; 2002, Cancer Res;62(12):3511-4
Deregulated DNA polymerase beta induces chromosome instability and tumorigenesis.
27. PMID: 29617664; 2018, Cell Rep;23(1):239-254.e6
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.
28. PMID: 24770870; 2014, Mol Cancer Res;12(8):1128-39
Base excision repair defects invoke hypersensitivity to PARP inhibition.
29. PMID: 24462520; 2014, Mol Oncol;8(3):520-32
DNA polymerase β deficiency is linked to aggressive breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression in multiple cohorts.
30. PMID: 19330779; 2009, J Surg Oncol;100(3):261-6
A platinum agent resistance gene, POLB, is a prognostic indicator in colorectal cancer.
31. PMID: 24739573; 2014, Nat Rev Cancer;14(5):359-70
Unravelling mechanisms of p53-mediated tumour suppression.
32. PMID: 21125671; 2011, J Pathol;223(2):137-46
Haplo-insufficiency: a driving force in cancer.
33. PMID: 22713868; 2012, Genes Dev;26(12):1268-86
Mutant p53: one name, many proteins.
34. PMID: 26181206; 2015, Cell Death Dis;6():e1826
Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF).
35. PMID: 22114072; 2012, Carcinogenesis;33(2):442-51
Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
36. PMID: 14743206; 2004, Oncogene;23(13):2330-8
Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
37. PMID: 27998224; 2016, J Clin Oncol;34(36):4354-4361
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.

ACT Onco[®] + Report

38. PMID: 26646755; 2016, Ann Oncol;27(3):539-43
TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
39. PMID: 25669829; 2015, Ann Oncol;26(5):1012-8
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
40. PMID: 27466356; 2016, Mol Cancer Ther;15(10):2475-2485
TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics.
41. PMID: 23670029; 2013, Oncotarget;4(5):705-14
P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy.
42. PMID: 17145525; 2006, Semin Oncol;33(5 Suppl 10):S8-14
Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
43. PMID: 21399868; 2011, Int J Oncol;38(5):1445-52
p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer.
44. PMID: 20549698; 2011, Int J Cancer;128(8):1813-21
p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.
45. PMID: 10786679; 2000, Cancer Res;60(8):2155-62
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
46. PMID: 25672981; 2015, Cancer Res;75(7):1187-90
VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy.
47. PMID: 25385265; 2015, Int J Oncol;46(2):607-18
TP53 oncomorphic mutations predict resistance to platinum and taxane based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
48. PMID: 31776133; 2020, Cancer Res;80(3):394-405
Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.
49. PMID: 28232952; 2017, NPJ Breast Cancer;3():
Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer.
50. PMID: 32343890; 2020, N Engl J Med;382(22):2091-2102
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
51. PMID: 31851799; 2019, N Engl J Med;381(25):2416-2428
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
52. PMID: 31157963; 2019, N Engl J Med;381(4):317-327
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
53. PMID: 30345884; 2018, N Engl J Med;379(26):2495-2505
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
54. PMID: 28578601; 2017, N Engl J Med;377(6):523-533
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
55. PMID: 28754483; 2017, Lancet Oncol;18(9):1274-1284
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

ACT Onco[®] + Report

56. PMID: 27617661; 2016, Lancet Oncol;17(11):1579-1589
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.